Literature DB >> 29923779

Reply letter to "Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab".

Alexandra W Dretler1, Nadine G Rouphael1, David S Stephens2.   

Abstract

Entities:  

Year:  2018        PMID： 29923779      PMCID： PMC6314420          DOI： 10.1080/21645515.2018.1491247

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  8 in total

1.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

2.  Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.

Authors:  Meltem Polat; Selçuk Yüksel; Nuriye Ünal Şahin
Journal:  Hum Vaccin Immunother       Date:  2018-06-29       Impact factor: 3.452

3.  Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.

Authors:  Noelle Cullinan; Kathleen Mary Gorman; Michael Riordan; Mary Waldron; Timothy H J Goodship; Atif Awan
Journal:  Pediatrics       Date:  2015-05-04       Impact factor: 7.124

4.  Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab.

Authors:  Sydel R Parikh; Jay Lucidarme; Coralie Bingham; Paul Warwicker; Tim Goodship; Ray Borrow; Shamez N Ladhani
Journal:  Pediatrics       Date:  2017-08-11       Impact factor: 7.124

5.  Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Amanda C Cohn; Jessica R MacNeil; Thomas A Clark; Ismael R Ortega-Sanchez; Elizabeth Z Briere; H Cody Meissner; Carol J Baker; Nancy E Messonnier
Journal:  MMWR Recomm Rep       Date:  2013-03-22

6.  Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  Temitope Folaranmi; Lorry Rubin; Stacey W Martin; Manisha Patel; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-12       Impact factor: 17.586

7.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

Authors:  Lucy A McNamara; Nadav Topaz; Xin Wang; Susan Hariri; LeAnne Fox; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

8.  Antibodies to watch in 2018.

Authors:  Hélène Kaplon; Janice M Reichert
Journal:  MAbs       Date:  2018-01-16       Impact factor: 5.857
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.